Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia

Journal of Clinical Oncology

Volumn 25, Issue 35, 2007, Pages 5616-5623

  Hillmen, Peter ^a   Skotnicki, Aleksander B ^a   Robak, Tadeusz ^a   Jaksic, Branimir ^a   Dmoszynska, Anna ^a   Wu, Jingyang ^a   Sirard, Cynthia ^a   Mayer, Jiri ^a  

^a LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTIVIRUS AGENT; CHLORAMBUCIL;

ADULT; AGED; ANEMIA; ARTICLE; BRONCHOPNEUMONIA; BRONCHOSPASM; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ENCEPHALITIS; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEART ARREST; HEMOLYTIC ANEMIA; HUMAN; HYPOTENSION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RISK ASSESSMENT; SEPSIS; SINUS BRADYCARDIA; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUBERCULOSIS; URTICARIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; BACTEREMIA; CHLORAMBUCIL; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUTROPENIA;

EID: 37649004407     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.12.9098     Document Type: Article

References (43)

1. Döhner H, Stilgenbauer S, Benner A, et al: Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343:1910-1916, 2000
2. Chemotherapeutic options in chronic lymphocytic leukemia: A meta-analysis of the randomized trials: CLL Trialists' Collaborative Group. J Natl Cancer Inst 91:861-868, 1999
3. Robak T, Blonski JZ, Kasznicki M, et al: Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: Report of a prospective, randomized, multicenter trial. Blood 96:2723-2729, 2000
4. Johnson S, Smith AG, Loffler H, et al: Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia: The French Cooperative Group on CLL. Lancet 347:1432-1438, 1996
5. Rai KR, Peterson BL, Appelbaum FR, et al: Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 343:1750-1757, 2000
6. Steurer M, Pall G, Richards S, et al: Purine antagonists for chronic lymphocytic leukaemia. Cochrane Database Syst Rev 3:CD004270, 2006
7. Zhu Q, Tan DC, Samuel M, et al: Fludarabine in comparison to alkylator-based regimen as induction therapy for chronic lymphocytic leukemia: A systematic review and meta-analysis. Leuk Lymphoma 45:2239-2245, 2004
8. Moreton P, Kennedy B, Lucas G, et al: Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 23:2971-2979, 2005
9. Wattel E, Preudhomme C, Hecquet B, et al: p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 84:3148-3157, 1994
10. Döhner H, Fischer K, Bentz M, et al: p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 85:1580-1589, 1995
11. Cordone I, Masi S, Mauro FR, et al: p53 expression in B-cell chronic lymphocytic leukemia: A marker of disease progression and poor prognosis. Blood 91:4342-4349, 1998
12. Lens D, Dyer MJ, Garcia-Marco JM, et al: p53 abnormalities in CLL are associated with excess of prolymphocytes and poor prognosis. Br J Haematol 99:848-857, 1997
13. Levine AJ: p53, the cellular gatekeeper for growth and division. Cell 88:323-331, 1997
14. Treumann A, Lifely MR, Schneider P, et al: Primary structure of CD52. J Biol Chem 270:6088-6099, 1995
15. Gilleece MH, Dexter TM: Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood 82:807-812, 1993
16. Keating MJ, Flinn I, Jain V, et al: Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: Results of a large international study. Blood 99:3554-3561, 2002
17. Stilgenbauer S, Döhner H: Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N Engl J Med 347:452-453, 2002
18. Lozanski G, Heerema NA, Flinn IW, et al: Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 103:3278-3281, 2004
19. Osuji NC, Del GI, Matutes E, et al: The efficacy of alemtuzumab for refractory chronic lymphocytic leukemia in relation to cytogenetic abnormalities of p53. Haematologica 90:1435-1436, 2005
20. O'Brien SM, Kantarjian HM, Thomas DA, et al: Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 98:2657-2663, 2003
21. Montillo M, Schinkoethe T, Elter T: Eradication of minimal residual disease with alemtuzumab in B-cell chronic lymphocytic leukemia (B-CLL) patients: The need for a standard method of detection and the potential impact of bone marrow clearance on disease outcome. Cancer Invest 23:488-496, 2005
22. Lundin J, Kimby E, Bjorkholm M, et al: Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 100:768-773, 2002
23. Karlsson C, Norin S, Kimby E, et al: Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukemia: Long-term follow-up of clinical effects, infectious complications and risk of Richter transformation. Leukemia 20:2204-2207, 2006
24. Cheson BD, Bennett JM, Grever M, et al: National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 87:4990-4997, 1996
25. Eichhorst BF, Busch R, Hopfinger G, et al: Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 107:885-891, 2006
26. Flinn IW, Neuberg DS, Grever MR, et al: Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol 25:793-798, 2007
27. Byrd JC, Peterson BL, Morrison VA, et al: Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: Results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 101:6-14, 2003
28. Keating MJ, O'Brien S, Albitar M, et al: Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 23:4079-4088, 2005
29. Byrd JC, Rai K, Peterson BL, et al: Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: An updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 105:49-53, 2005
30. Hainsworth JD, Litchy S, Barton JH, et al: Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: A phase II trial of the Minnie Pearl Cancer Res Network. J Clin Oncol 21:1746-1751, 2003
31. Montillo M, Tedeschi A, Miqueleiz S, et al: Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. J Clin Oncol 24:2337-2342, 2006
32. Montillo M, Cafro AM, Tedeschi A, et al: Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine. Haematologica 87:695-700, 2002
33. O'Brien SM, Keating MJ, Mocarski ES: Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab. Clin Lymphoma Myeloma 7:125-130, 2006
34. Elter T, Borchmann P, Schulz H, et al: Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: Results of a phase II trial. J Clin Oncol 23:7024-7031, 2005
35. Kennedy B, Rawstron A, Carter C, et al: Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood 99:2245-2247, 2002
36. Faderl S, Thomas DA, O'Brien S, et al: Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 101:3413-3415, 2003
37. Nabhan C, Patton D, Gordon LI, et al: A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL). Leuk Lymphoma 45:2269-2273, 2004
38. Wierda W, Faderl S, O'Brien S, et al: Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR) is active for relapsed and refractory patients with CLL. Blood 104, 2004 (abstr 340)
39. Thieblemont C, Bouafia F, Hornez E, et al: Maintenance therapy with a monthly injection of alemtuzumab prolongs response duration in patients with refractory B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL). Leuk Lymphoma 45:711-714, 2004
40. Rai K, Byrd J, Peterson BL, et al: Subcutaneous alemtuzumab following fludarabine for previously untreated patients with chronic lymphocytic leukemia (CLL): CALGB Study 19901. Blood 102, 2003 (abstr 2506)
41. Wendtner CM, Ritgen M, Schweighofer CD, et al: Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission: Experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia 18:1093-1101, 2004
42. Liggett WH, Hainsworth JD, Spigel DR, et al: Fludarabine/rituximab (FR) followed by alemtuzumab as first-line treatment for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL): A Minnie Pearl Cancer Res Network phase II trial. J Clin Oncol 23:574s, 2005 (abstr 6556)
43. Wierda WG, Kipps TJ, Keating MJ, et al: Self-administered, subcutaneous (SQ) alemtuzumab to eliminate residual disease in patients (pts) with CLL. Blood 108, 2006 (abstr 2839)